Search form
Search
contact us
Navigation
home
boards
Jobs
job ratings
cp wire
medtech news
pharmagather
catering
advertise
whistleblower info
pharmaceutical fraud
medical device | DME fraud
clinical lab fraud
False Claims Act
Legal Help
login/register
You are here
Home
» Axovant Bets on Gene Therapy With $842 Million Deal With Oxford BioMedica
Axovant Bets on Gene Therapy With $842 Million Deal With Oxford BioMedica
Axovant Bets on Gene Therapy With $842 Million Deal With Oxford BioMedica
Submitted by
admin
on June 6, 2018 - 9:29am
Source:
CP Wire
News Tags:
Axovant
Oxford BioMedica
AXO-Lenti-PD
Pro-Savin
Headline:
Axovant Bets on Gene Therapy With $842 Million Deal With Oxford BioMedica
snippet:
Axovant will license two products from Oxford BioMedica
The gene therapy based products have demonstrated long term improvement in motor function
Axovant shares are up 102% in premarket trading
Do Not Allow Advertisers to Use My Personal information
